The S&P 500 index closed higher on Monday as investors were still optimistic over trade talks between the United States and ...

On Monday, analysts at Morgan Stanley reiterated their Overweight rating on Gilead Sciences, Inc. (NASDAQ:GILD), while ...

Gilead's twice-yearly HIV injection faces headwinds from US aid pullback. Thank you for reading Nation.Africa Show plans Gilead Sciences says it still plans to supply its twice-yearly injection for ...

The Trump administration has moved to end funding for a broad swath of HIV vaccine research, saying current approaches are ...

Arguably the most notable of the FDA’s upcoming decisions is that regarding Gilead’s twice-yearly HIV prophylaxis lenacapavir ...

Gilead Sciences is paying $10 million for sole ownership of arenavirus immunotherapies for hepatitis B (HBV) and HIV ...

At current levels, we recommend prospective investors to opt for GSK as compared to GILD on the back of a strong and wide portfolio, upcoming product launches, promising pipeline candidates and recent ...

The administration of Donald Trump has reportedly terminated funding for several HIV vaccine research programs.

Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps such as inventory ...

Gilead Sciences says it still plans to supply its twice-yearly injection for preventing HIV infection in low-income countries if it wins U.S. approval despite funding uncertainty over the Trump ...